Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. EXCLUSIVE LICENSE AGREEMENT BY AND BETWEEN TREVI THERAPEUTICS, INC. AND PENWEST PHARMACEUTICALS CO.Exclusive License Agreement • November 19th, 2018 • Trevi Therapeutics, Inc. • Pharmaceutical preparations • Pennsylvania
This Exclusive License Agreement is entered into this 13th day of May, 2011 (the “Effective Date”), by and between Trevi Therapeutics, Inc,, a Delaware company, with principal offices located at 52 Charter Ridge Drive, Sandy Hook, CT 06482 (“Trevi”) and Penwest Pharmaceuticals Co,, a Washington corporation, with principal offices located at 100 Endo Boulevard, Chadds Ford, PA 19317 (“Penwest”). Each of Trevi and Penwest may be referred to, individually, as a “Party”, and, collectively, as the “Parties”.
TREVI THERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • November 19th, 2018 • Trevi Therapeutics, Inc. • Pharmaceutical preparations • New York
This EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into by and between Trevi Therapeutics, Inc., a Delaware corporation (the “Company”) and Thomas R. Sciascia (the “Executive”) as of this 4th day of December, 2012.
First Amendment to LeaseLease • November 19th, 2018 • Trevi Therapeutics, Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT TO LEASE (“First Amendment”) dated December 5, 2017, by and between 195 Church Street Associates, LLC, a Connecticut limited liability corporation (“Landlord”) and Trevi Therapeutics, Inc. (“Tenant”).
Confidential Materials omitted and filed with the Securities and Exchange Commission. Asterisks denote omissions. EXCLUSIVE LICENSE AGREEMENT BETWEEN RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY AND TREVI THERAPEUTICS, INC. EFFECTIVE NOVEMBER 6, 2018Exclusive License Agreement • November 19th, 2018 • Trevi Therapeutics, Inc. • Pharmaceutical preparations • New Jersey
For the sake of clarity, each Milestone Payment is payable no more than once and only with respect to the first achievement of the relevant Milestone Event for a Licensed Product. In no event shall all Milestone Payments, in the aggregate, total more than $62,500. In no event shall any Milestone Payment be payable after the end of the expiration of the last Valid Claim of the Patent Rights.
TREVI THERAPEUTICS, INC. Nonstatutory Stock Option Agreement Granted Under 2012 Stock Incentive PlanAdoption Agreement • November 19th, 2018 • Trevi Therapeutics, Inc. • Pharmaceutical preparations
